Zealand Gains as Sanofi Will Speed Up Lyxumia: Copenhagen Mover

Zealand Pharma A/S, the Danish drugmaker, rose the most in seven weeks in Copenhagen trading after partner Sanofi said it will step up commitment to develop diabetes treatment Lyxumia as a rival drug faces setbacks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.